Upgrade to SI Premium - Free Trial

Biogen (BIIB) Reports Initiation of New Global Clinical Trial, DEVOTE, Evaluating Higher Dose of SPINRAZA (nusinersen) & Additional Data

September 18, 2019 7:34 AM
Biogen Inc. (NASDAQ: BIIB) today announced updates to the SPINRAZA (nusinersen) clinical development program including the initiation of a new ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Categories

Corporate News FDA Management Comments

Next Articles